Quattrocchi Valeria, Soria Ivana, Langellotti Cecilia Ana, Gnazzo Victoria, Gammella Mariela, Moore Dadin P, Zamorano Patricia I
Instituto de virología, CICVyA, INTA Castelar , Hurlingham, Buenos Aires , Argentina.
CONICET, CABA , Buenos Aires , Argentina.
Front Immunol. 2017 Jan 25;8:37. doi: 10.3389/fimmu.2017.00037. eCollection 2017.
Bovine herpesvirus-1 (BoHV-1) is the causative agent of bovine infectious rhinotracheitis, an important disease worldwide. Although conventional BoHV-1 vaccines, including those based on the use of modified live virus and also inactivated vaccines, are currently used in many countries, they have several disadvantages. DNA vaccines have emerged as an attractive approach since they have the potential to induce both humoral and cellular immune response; nevertheless, it is largely known that potency of naked DNA vaccines is limited. We demonstrated previously, in the murine model, that the use of adjuvants in combination with a DNA vaccine against BoHV-1 is immunologically beneficial. In this study, we evaluate the immune response and protection against challenge elicited in bovines, by a DNA vaccine carrying the sequence of secreted version of glycoprotein D (gD) of BoHV-1 formulated with chemical adjuvants. Bovines were vaccinated with formulations containing the sequence of gD alone or in combination with adjuvants ESSAI 903110 or Montanide™ 1113101PR. After prime vaccination and two boosters, animals were challenged with infectious BoHV-1. Formulations containing adjuvants Montanide™ 1113101PR and ESSAI 903110 were both, capable of increasing humoral immune response against the virus and diminishing clinical symptoms. Nevertheless, only formulations containing adjuvant Montanide™ 1113101PR was capable of improving cellular immune response and diminishing viral excretion. To our knowledge, it is the first time that a BoHV-1 DNA vaccine is combined with adjuvants and tested in cattle. These results could be useful to design a vaccine for the control of bovine rhinotracheitis.
牛疱疹病毒1型（BoHV-1）是牛传染性鼻气管炎的病原体，这是一种在全球范围内的重要疾病。尽管目前许多国家使用传统的BoHV-1疫苗，包括基于使用减毒活病毒的疫苗以及灭活疫苗，但它们存在若干缺点。DNA疫苗已成为一种有吸引力的方法，因为它们有可能诱导体液免疫和细胞免疫反应；然而，众所周知，裸DNA疫苗的效力有限。我们之前在小鼠模型中证明，将佐剂与针对BoHV-1的DNA疫苗联合使用在免疫方面是有益的。在本研究中，我们评估了携带BoHV-1糖蛋白D（gD）分泌型序列的DNA疫苗与化学佐剂一起配制后在牛中引发的免疫反应和对攻击的保护作用。用单独含有gD序列或与佐剂ESSAI 903110或Montanide™ 1113101PR联合的制剂对牛进行免疫接种。在初次免疫接种和两次加强免疫后，用传染性BoHV-1对动物进行攻击。含有佐剂Montanide™ 1113101PR和ESSAI 903110的制剂都能够增强针对该病毒的体液免疫反应并减轻临床症状。然而，只有含有佐剂Montanide™ 1113101PR的制剂能够改善细胞免疫反应并减少病毒排泄。据我们所知，这是首次将BoHV-1 DNA疫苗与佐剂联合并在牛中进行测试。这些结果可能有助于设计一种用于控制牛鼻气管炎的疫苗。
